13. Why hasn’t there been a major agent launched in this market for so long?

We can’t speculate on the business decisions of other companies, but the development of drugs for the treatment of AF is extremely complex and led to clinical development discontinuations. Sanofi-aventis continues to be committed to the development of innovative therapies that improve clinical outcomes and provide new hope to more patients burdened with a wide range of cardiovascular diseases.